French researchers found that children with neonatal diabetes who were given glibenclamide oral suspension after initial dosage of glibenclamide tablets had similar HbA1C and incidence of hypoglycemia or hyperglycemia after four months than at baseline. The findings in Pediatric Diabetes also showed that the oral suspension therapy was preferred by younger children, while tablets were preferred by those who were older.
Study evaluates glibenclamide oral suspension in neonatal diabetes
Sign up for AANP SmartBrief
News for nurse practitioners
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.